BOEHRINGER INGELHEIM ENTERS GLOBAL LICENSING AGREEMENT TO DEVELOP AND COMMERCIALIZE INNOVATIVE ANTIBODIES FROM A*STAR FOR TARGETED CANCER THERAPIES

Source :: Business Wire India (Delhi-NCR, India). June 3, 2022
Publication Year :: 2022
Abstract: Atlanta, June 3 -- Boehringer Ingelheim gains exclusive global rights to a panel of cancer-specific antibodies to enable the development of targeted cancer therapies These engineered antibodies may allow for [...]

Subjects :: Boehringer Ingelheim GmbH -- Licensing agreements -- International marketing
T cells -- Health aspects
Biological products -- International marketing -- Licensing agreements
Antineoplastic agents -- Licensing agreements -- International marketing
Viral antibodies -- Health aspects
Cancer -- Health aspects
Antibodies -- Health aspects
Pharmaceutical industry -- International marketing -- Licensing agreements
Antimitotic agents -- Licensing agreements -- International marketing
Company licensing agreement
Business, international

Tools